In vitro activity of azoxystrobin, dimethomorph, and fluazinam on growth, sporulation, and zoospore cyst germination of Phytophthora capsici, P. citrophthora, and P. parasitica was compared to that of fosetyl-Al and metalaxyl. The 50% effective concentration (EC 50 ) values for)inhibition of mycelial growth of the three pathogens usually were lowest for dimethomorph and (metalaxyl, ranging from <0.1 to 0.38 μg/ml. However, the 90% effective concentration (EC 90 ) levels for dimethomorph always were lower than the other four tested compounds, with values ranging from 0.32 to 1.6 μg/ml. Mycelial growth of P. capsici, P. citrophthora, and P. parasitica was least affected by azoxystrobin and fluazinam, with estimated (EC 90 ) values >3,000 μg/ml. Reduction of sporangium formation by P. capsici, P. citrophthora, and P. parasitica in the presence of dimethomorph at 1 μg/ml was significantly greater than that recorded for the same concentration of azoxystrobin, fluazinam, and fosetyl-Al. For the three species of Phytophthora, zoospore motility was most sensitive to fluazinam (EC 50 and EC 90 values of <0.001 μg/ml) and (least sensitive to fosetyl-Al, with (EC 50 and EC 90 values ranging from 299 to 334 and 518 to 680 μg/ml, respectively). Germination of encysted zoospores of P. capsici, P. citrophthora, and P. parasitica was most sensitive to dimethomorph (EC 50 and EC 90 values ranging from 3.3 to 7.2 and 5.6 to 21 μg/ml, respectively), intermediate in sensitivity to fluazinam (EC 50 and EC 90 from 18 to 108 and 67 to >1,000 μg/ml, respectively) and metalaxyl (EC 50 and EC 90 from 32 to 280 and 49 to 529 μg/ml, respectively), and lowest in sensitivity to azoxystrobin and fosetyl-Al (EC 50 and EC 90 from 256 to >1,000 μg/ml). The activity of azoxystrobin, dimethomorph, and fluazinam on one or more stages of the life cycle of P. capsici, P. citrophthora, and P. parasitica suggests that these compounds potentially could provide Phytophthora spp. disease control comparable to that of the established fungicides fosetyl-Al and metalaxyl.
No takes yet. Share an insight, caveat, or question.
Matheron et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: